デシタビンは,まれなメラノーマにおける先天的な免疫遺伝子の抑制を逆転させる

Morgan L MacBeth, Stacey M Bagby, Jessica S W Borgers

bioRxiv : the preprint server for biology

|September 5, 2025

まとめ

治療反応を阻害する免疫信号を抑制している. 低甲基化DNA剤であるデシタビンはこれらの経路を活性化させ稀なメラノーマの免疫療法に新たな戦略を提示します

科学分野:

腫瘍学
免疫学
ゲノミクス

背景:

免疫チェックポイント阻害剤 (ICI) に対する反応は低い.
希少メラノーマにおけるICI耐性の分子基礎はほとんど不明である.

研究の目的:

腫瘍内遺伝子発現を希少性メラノーマと皮膚性メラノーマと比較する.
珍しいメラノーマの免疫回避の分子メカニズムを特定する.
稀なメラノーマに対する免疫調節療法としてデシタビンを評価する.

主な方法:

患者からの異種移植 (PDX) と公的なデータセットのトランスクリプトミックプロファイリング.
免疫細胞の浸透分析のためのCIBERSORT解体
デシタビンによる体内および体内の薬物スクリーニング

主要な成果:

希少なメラノーマは,先天性免疫病原体感知 (IIPS) とタイプIインターフェロン信号が低下している.
下のIIPS遺伝子発現は,CD8+T細胞の減少とM2マクロファージの増加と相関する.
デシタビン治療は,IVPSと適応性免疫遺伝子発現を in vitro と in vivo で強力に誘導した.

結論:

IIPS遺伝子の静止は,希少なメラノーマの免疫回避の重要なメカニズムです.
デシタビンはIIPS遺伝子を再発し,ICI治療の強化の可能性を示唆する.
デシタビンは珍しいメラノーマの治療において有望な免疫調節戦略です.

さらに関連する動画

10:49

A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers

Published on: September 26, 2019

5.7K

07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

11.2K

関連する概念動画

02:57

Targeted Cancer Therapies

7.8K

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

7.8K

02:50

Combination Therapies and Personalized Medicine

5.1K

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

5.1K

01:20

The Retinoblastoma Gene

4.2K

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

4.2K

01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

7.9K

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...

7.9K

02:56

Treatment Resistant Cancers

3.4K

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...